Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Barriers to accepting e-prescribing in the U.S.A.

Alan D Smith1

  • 1Department of Management and Marketing, Robert Morris University, Pittsburgh, Pennsylvania, USA. smitha@rmu.edu

International Journal of Health Care Quality Assurance Incorporating Leadership in Health Services
|August 1, 2006
PubMed
Summary

Electronic prescribing (e-prescribing) streamlines medication orders and reduces errors. Customer Relationship Management (CRM) and ethics significantly influence willingness to purchase prescriptions online, despite industry barriers.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2022
Same author

Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies.

Expert review of anticancer therapy·2022
Same author

Assessing the Safety and Efficacy of Two Starting Doses of Lenvatinib Plus Everolimus in Patients with Renal Cell Carcinoma: A Randomized Phase 2 Trial.

European urology·2022
Same author

Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer.

The New England journal of medicine·2022
Same author

Updating an empirical investigating risk perceptions associated with national ID cards in the wake of the global Covid-19 pandemic.

Health marketing quarterly·2021
Same author

Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.

The Lancet. Oncology·2021

Area of Science:

  • Health Informatics
  • Pharmacy Practice
  • Information Systems

Background:

  • Prescription numbers are rising nationally.
  • Web-based technology adoption in pharmacy is surprisingly low.
  • Traditional prescription handling is manual and prone to errors.

Purpose of the Study:

  • To investigate the phenomena of electronic prescribing (e-prescribing) in the U.S.A.
  • To analyze factors influencing the adoption of e-prescribing.
  • To understand the potential of e-prescribing to improve quality and reduce errors.

Main Methods:

  • Principal-components analysis (PCA) and factor analyses were employed.
  • A sample of 55 college-educated professionals in Pittsburgh was selected.
  • Hypotheses were tested using regression analysis.

Related Experiment Videos

Main Results:

  • Six major constructs were identified: profit/risk, shipping, savings, CRM/ethics, age, and awareness.
  • Overall relationship between constructs and willingness to use e-prescribing was significant (F=2.971, p=0.015).
  • Customer Relationship Management (CRM) and ethics significantly predicted willingness to purchase online (t=-3.074, p=0.003).

Conclusions:

  • E-prescribing adoption faces barriers like technology trust, costs, and data security concerns.
  • Pharmacies are increasingly building IT infrastructures for electronic prescriptions.
  • E-prescribing has the potential to enhance physician prescribing globally by providing access to patient records.